| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2012: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2010: ¥8,060,000 (Direct Cost: ¥6,200,000、Indirect Cost: ¥1,860,000)
|
|---|
| Research Abstract |
Recent several lines of evidence have suggested that the concept regarding “cancer stem cell" is associated with the pathogenesis of drug-resistant or cancer recurrence. However, a little is known about how Oct3/4, Sox2, Klf-4, c-Myc and tumor suppressor p53 can regulate pluripotency and reprogramming process. Here, we have focused on p53 and Yamanaka 4 factors, and attempted to elucidate the common epigenetic mechanism between cancer stem cells and iPS/ES cells by the combination of cross-linking methodology and genome-wide analysis. Trascriptome analysis revealed the identification of cancer and iPS specific non-coding RNA including long intergenic RNA (linc RNA) as well as GLS2 which are important for the maintenance of stemness. Furthermore, we found the tumor suppressor and anti-metastatic function of certain genes in vitro and in
|
